SABCS Reaction
December 9, 2022

SABCS Reactions - DESTINY-Breast03

SABCS Reaction
December 12, 2022

SABCS Reactions - DESTINY-Breast03

Author

Abstract #GS2-02: Sara Hurvitz  presented updated survival and safety results of the P3 DESTINY-Breast03 trial, assessing trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in 524 patients with HER2+ mBC previously treated with an anti-HER2 therapy.

Results:

  • Risk of death reduced by 36% with T-DXd
  • OS with T-DXd significantly higher vs T-DM1 (69.3 vs 55.4% at 36 mos); median OS not yet reached
  • Median PFS significantly longer for T-DXd vs T-DM1 (28.8 vs. 6.8 mos, respectively)
  • Confirmed ORR for T-DXd significantly higher vs T-DM1 (78.5 vs 35.0%)
  • Grade ≥3 TEAE experienced by 56.4% of T-DXd-treated pts vs 51.7% of T-DM1-treated pts; no grade 4 or 5 events were observed in T-DXd arm
  • Drug-related interstitial lung disease (ILD) experienced by 15.2% in the T-DXd arm vs 3.1% in the T-DM1 arm
  • Thought leader reactions were very positive; the 36%reduction in death risk with clinically significant improvement in PFS and OS rates with T-DXd over T-DM1excited several oncologists.

    With disease control four times longer than T-DM1, thought leaders consider T-DXd to be the preferred 2L option in HER2+mBC.

    Other thought leaders cited no deaths from ILD, fewer cumulative toxicities, and fewer discontinuations as other advantages of T-DXd over T-DM1.

    Summary: Citing significant efficacy advantages of T-DXd over T-DM1, thought leaders consider T-DXd as the preferred second line therapy in HER2+ mBC previously treated with an anti-HER2therapy.

    Synthesis powered by Opus Strategy, LLC.

    Download attached file
    Not rated
    Allison Betof Warner, MD, PhD (she/her) 4
    3743
    Manhattan, NY
    November 10, 2022

    79% had reduction in disease. ORR 31%. Many responses deepen over time.

    Not rated
    Allison Betof Warner, MD, PhD (she/her) 3
    3743
    Manhattan, NY
    November 10, 2022

    Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

    Positive
    Alex Shoushtari, MD
    2253
    New York, USA
    November 10, 2022

    Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

    Not rated
    Allison Betof Warner, MD, PhD (she/her) 2
    3743
    Manhattan, NY
    November 10, 2022

    Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

    Positive
    Hussein Tawbi, MD, PhD
    1685
    Houston, TX
    November 10, 2022

    Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

    Positive
    Allison Betof Warner, MD, PhD (she/her) 1
    3744
    Manhattan, NY
    November 10, 2022

    Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

    Not Rated
    Sumanta K. Pal, MD, FASCO
    15083 Followers
    Los Angeles, CA
    November 8, 2022

    Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

    not rated
    Shilpa Gupta
    5095 Followers
    Cleveland, OH
    November 8, 2022
    Not Rated
    Tian Zhang, MD, MHS
    6463 Followers
    Dallas, TX
    November 8, 2022

    CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

    Not Rated
    Moshe Ornstein MD
    1930 Followers
    Cleveland, OH
    November 8, 2022

    Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

    Not Rated
    Shuchi Gulati MD
    12476 Followers
    Seattle, WA
    November 8, 2022

    Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

    Not Rated
    Petros Grivas
    12476 Followers
    Seattle, WA
    November 8, 2022

    Subscribe to our newsletter

    Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
    Thank you! Your submission has been received!
    Oops! Something went wrong while submitting the form.